Top Markets
Coin of the day
BioLineRx Ltd. BioLineRx Ltd.

BioLineRx Ltd.

BLRX
Rank in Stocks #40526
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and... BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Share Price
$0.0048574
Market Cap
$126.82K
Change (1 day)
0.00%
Change (1 year)
-21.82%
Country
IL
Trade BioLineRx Ltd. (BLRX)

Category

P/B ratio for BioLineRx Ltd. (BLRX)
P/B ratio as of 2026 TTM: 0
According to BioLineRx Ltd. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for BioLineRx Ltd. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE